ClinicalTrials.gg
RecruitingNCT06387199SEMA SMAUpdated Nov 19, 2026

Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide

A Phase 2/3 interventional study of Semaglutide with 4 meal strategies and Placebo with 4 meal strategies in Type 1 Diabetes and Diabetes Mellitus, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2/3, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Nov 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
33
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre — 7 open to participants now, 7 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · McGill University Health Centre/Research Institute of the McGill University Health Centre.

Planned enrollment
7th of 12
33 · median 34
Started
2024
with 2 others
Phase 2/3
5 of 15
4 open now
Registered
12th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 2/3, and was the 12th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

7 of the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, or all of them as a file.
02

Study summary

A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose levels. Primarily designed for managing type 1 diabetes, this system has demonstrated significant benefits in previous studies. Yet, despite these advantages, certain challenges persist.

Semaglutide, utilized in treating type 2 diabetes and obesity, is a once-weekly injectable medication that elevates levels of a gastrointestinal hormone known as Glucagon-Like Peptide-1 (GLP-1). This hormone alters gastric emptying, inhibits glucagon release, and reduces appetite. While not officially sanctioned for type 1 diabetes treatment in North America, studies have explored its efficacy as an adjunctive therapy alongside insulin, yielding favorable outcomes in blood glucose regulation. Comparable drugs like liraglutide and exenatide have been employed in type 1 diabetes treatment as well, albeit with less pronounced glucose-regulating effects compared to semaglutide, even in type 2 diabetes.

The goal of this 50-week randomized placebo-controlled crossover 2x4 factorial designed trial is to assess whether commercial automated insulin delivery (AID) systems using rapid-acting insulin with adjunct weekly injections of semaglutide (at the maximally tolerated dose) can replace carbohydrate counting with simple meal announcements (SMA) without degrading glucose control.

Read the detailed description

The main questions this study aims to answer are:

  • Can weekly injections of semaglutide at the maximum tolerated dose in individuals with T1D on closed-loop therapy with SMA and rapid-acting insulin result in a non-inferior time spent in target range (3.9-10 mmol/L) compared to weekly placebo injections on closed-loop system with full carbohydrate counting.
  • Can weekly injections of semaglutide at the maximum tolerated dose, in combination with ultra-rapid actin insulin (Lyumjev);

    1. Eliminate carbohydrate counting and any meal announcement (i.e fully closed-loop) in people with T1D on closed-loop therapy without degrading glucose control.
    2. Be more effective in substituting carbohydrate counting with SMA in people with T1D on closed-loop therapy compared with traditional rapid-acting insulin.

Participants will be asked to undergo two subsequent blinded drug interventions; one with semaglutide and the other with placebo. Both interventions include 4 meal strategies each with a 3-week duration; full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev.

03

Conditions studied

  • Type 1 Diabetes
  • Diabetes Mellitus

Keywords

  • insulin
  • Closed-loop system
  • GLP-1 receptor agonist
  • Semaglutide
  • Diabetes mellitus, type 1
  • ozempic
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age
  2. A clinical diagnosis of T1D for at least one year, as per their treating diabetes physician in agreement with the primary investigator's clinical judgment (confirmatory C-peptide and antibodies will not be required)
  3. Minimum 3-month use of a commercial advanced automated insulin delivery system. 4.4. Agreement to use an effective method of for individuals with . Child-bearing potential refers to participants of the female sex post-menarche who have not reached menopause and who do not have a medical condition causing sterility (e.g., hysterectomy). state refers to the absence of menses for 12 months without any alternative cause.

Exclusion criteria

Exclusion Criteria:

  1. Use of GLP1-RAs within the last 4 weeks.
  2. Use of any anti-hyperglycemic agent other than insulin within the last 2 weeks.
  3. Planned or ongoing pregnancy
  4. Breastfeeding
  5. Severe hypoglycemic episode within the last 3 months, defined as an event where glucose was \< 4 mmol/L resulting in seizure, loss of consciousness, or need to present to the emergency department
  6. Severe diabetic ketoacidosis (DKA) within the last 6 months ("severe" referring to need to present to medical attention and requirement of intravenous insulin)
  7. Prior history of acute pancreatitis, chronic pancreatitis, or gallbladder disease
  8. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
  9. Severe impairment of renal function with \<30 mL/min/1.73 m2 (using CKD-EPI formula), measured within the last 12 months
  10. diabetic retinopathy or gastroparesis, as per the clinical judgment of the investigator
  11. Bariatric surgery within the last 6 months.
  12. A serious medical or psychiatric illness that is likely to interfere with study participation as per the judgment of the investigator (e.g. cirrhosis, active cancer, decompensated schizophrenia).
  13. ≤ 21 kg/m2
  14. Inability or unwillingness to comply to safe diabetes management in the view of the study group (e.g. inappropriate treatment of hypoglycemia or lack thereof)
  15. Concern for safety of the participant, as per the clinical judgment of the primary investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (estimated)

Study arms

  • Active comparator
    Weekly placebo injections on regular closed-loop insulin pump therapy

    Drug: Placebo with 4 meal strategies

  • Experimental
    Weekly semaglutide (Ozempic®) injections on regular closed-loop insulin pump therapy

    Semaglutide is a Glucagon-like peptide 1 (GLP-1) receptor agonist. It up regulates GLP-1, which reduces glucagon levels, increases satiety and - in some particular cases - increases insulin production. It will be subcutaneously injected weekly by participants at progressively increasing doses. Once the maximum tolerated dose is achieved, participants will begin the meal strategies.

    Drug: Semaglutide with 4 meal strategies

Interventions

  • DrugSemaglutide with 4 meal strategies

    The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.

  • DrugPlacebo with 4 meal strategies

    The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo)

    Target range is defined to be between 3.9 and 10.0 mmol/L of plasma glucose for placebo vs semaglutide (at maximal tolerated dose) on closed-loop insulin therapy

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of time spent in the range of glucose levels between 3.9 and 7.8 mmol/L

    % as per CGM data

    Time frame: 24 weeks

  2. Percentage of time spent in glucose levels below 3.9 and 3.0 mmol/L

    % as per CGM data

    Time frame: 24 weeks

  3. Percentage of time spent in glucose levels above 7.8, 10 and 13.9 mmol/L

    % as per CGM data

    Time frame: 24 weeks

  4. Mean glucose level

    Defined as per CGM data, in mmol/L

    Time frame: 24 weeks

  5. Standard deviation of glucose levels as a measure of glucose variability

    Defined as per CGM data, in mmol/L

    Time frame: 24 weeks

  6. Percentage coefficient of variation of glucose levels

    % as per CGM data

    Time frame: 24 weeks

  7. Proportions of participants with time in range between 3.9 - 10.0 mmol/L≥ 70%

    As per CGM data

    Time frame: 24 weeks

  8. Glycated hemoglobin (HbA1c)

    Blood test to assess glucose control within 3-4 months

    Time frame: 24 weeks

  9. Area under the curve 0-2h post meal, 0-3h post peal

    As per CGM data

    Time frame: 24 weeks

  10. Average scores between interventions on the Type 1 Diabetes Distress Scale questionnaire

    17-item questionnaire with a 6-point Likert scale from 1 (no stress) to 6 (high stress) for each item. Total score obtained from summing the scores of all items

    Time frame: 24 weeks

  11. Average scores between interventions on the Diabetes Treatment Satisfaction questionnaire

    8-item questionnaire with a 7-point Likert scale ranging from 0 (low satisfaction) to 6 (high satisfaction). Total score obtained from summing the scores of all items.

    Time frame: 24 weeks

  12. Average scores between interventions based on the Hypoglycemic Fear Survey - II

    33-item questionnaire with a 5-point Likert scale ranging from 1 (never) to 5 (almost always). Total score obtained from summing the scores of all items.

    Time frame: 24 weeks

  13. Heart rate

    Beats per minute

    Time frame: 24 weeks

  14. Blood pressure

    mmHg

    Time frame: 24 weeks

  15. Measure of body weight

    Measurements done at visit - weight in kilograms

    Time frame: 24 weeks

  16. Measure of body mass index

    Measurements done at visit - body mass index as per kg/m\^2

    Time frame: 24 weeks

  17. Measure of waist circumference and hip circumference

    Measurements done at visit - circumference in cm

    Time frame: 24 weeks

  18. Measure of waist-to-hip ratio

    Measurements done at visit

    Time frame: 24 weeks

  19. Lipid profile, specifically: LDL-cholesterol, HDL-cholesterol, triglycerides

    Blood tests, in mmol/L

    Time frame: 24 weeks

  20. Urine albumin-creatinine ratio

    Urine test

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Research Institute of the McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
    • Carolyn Wright, B.Sc. · Contactcarolyn.wright@mail.mcgill.ca · (514) 318-7298
    • Michael Tsoukas, MD · Principal investigator
    • Ahmad Haidar, Ph.D · Sub investigator
    • Vanessa Tardio, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The raw data (that is, insulin delivery, glucose levels and individual participant data) and informed consent form will be shared by the corresponding author, for academic purposes, subject to a material transfer agreement and approval of the McGill University Health Center's Research Ethics Board. All data shared will be de-identified. Raw data will be shared for non-commercial use upon reasonable request and a material transfer agreement.

Supporting information: Informed consent form

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

Of 19 phase 2/3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 36 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jan 2027 → Dec 2027 and completion Jan 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 26, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Dec 2027was Jan 2027
CompletionEst.
Dec 2027was Jan 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2027→Dec 2027
Nov 19, 2026
Study completion
Jan 2027→Dec 2027
Nov 19, 2026
Enrollment
26→33
Nov 19, 2026
Contact
Study contact changed: g•••@rimuhc.ca · •••2171→c•••@mail.mcgill.ca · •••7298; n•••@mail.mcgill.ca · •••9455→k•••@affiliate.mcgill.ca · •••6896. See the current contact
Nov 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Research Institute of the McGill University Health Centre · Montreal, CanadaContact g•••@rimuhc.ca · •••2171→c•••@mail.mcgill.ca · •••7298Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Jan 2027→Dec 2027
    Study completion Jan 2027→Dec 2027
    Enrollment 26→33
    Contact Study contact changed: g•••@rimuhc.ca · •••2171→c•••@mail.mcgill.ca · •••7298; n•••@mail.mcgill.ca · •••9455→k•••@affiliate.mcgill.ca · •••6896. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Research Institute of the McGill University Health Centre · Montreal, CanadaContact g•••@rimuhc.ca · •••2171→c•••@mail.mcgill.ca · •••7298Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06387199
Responsible party
Michael Tsoukas (Assistant Professor, Endocrinology & Metaolism, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Apr 26, 2024
Start date
Dec 1, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Carolyn Wright, B.Sc.
Contact
carolyn.wright@mail.mcgill.ca
(514) 318-7298
Keddy Moise, B.Sc.
Contact
keddy.moise@affiliate.mcgill.ca
(438) 531-6896

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion